title: A phase II trial of 4-demethoxydaunorubicin in refractory epithelial ovarian cancer.
abstract: Sixteen evaluable patients with refractory epithelial ovarian cancer were treated with oral 4-demethoxydaunorubicin. The drug was given in divided doses over 5 days and dosage was repeated every 3 weeks. There were no objective remissions. Three patients had stabilized disease of 5 to 7 months duration. Although well tolerated, this anthracycline has modest effectiveness against previously treated ovarian cancer.
authors.forename: J J
authors.initials: JJ
authors.lastname: Kavanagh
authors.forename: L J
authors.initials: LJ
authors.lastname: Copeland
authors.forename: D M
authors.initials: DM
authors.lastname: Gershenson
authors.forename: P B
authors.initials: PB
authors.lastname: Saul
authors.forename: C L
authors.initials: CL
authors.lastname: Edwards
mesh_terms: D000328:Adult; D000368:Aged; D003630:Daunorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015255:Idarubicin; D007958:Leukocyte Count / Q000187:drug effects; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D015255:Idarubicin; D003630:Daunorubicin